A
ACADIA Pharmaceuticals Inc. (ACAD)
NMS – Real vaqt narxi. Valyuta: USD
21.72
-0.08 (-0.37%)
Yopilishda: May 12, 2026, 4:00 PM EDT
21.80
+0.08 (0.37%)
Bozor oldidan: May 13, 2026, 7:43 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
21.72
-0.08 (-0.37%)
Yopilishda: May 12, 2026, 4:00 PM EDT
21.80
+0.08 (0.37%)
Bozor oldidan: May 13, 2026, 7:43 AM EDT
ACADIA Pharmaceuticals Inc., biotexnologiya kompaniyasi, Shimoliy Amerikada nevrologik va kam uchraydigan kasalliklar uchun dori vositalarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya Parkinson kasalligi psixoziga bog'liq bo'lgan gallyutsinatsiyalar va alahsidlar davolash uchun selektiv serotonin inverse agonisti/antagonisti bo'lgan NUPLAZID (pimavanserin) va neyroinflamatsiyani kamaytirish hamda sinaptik funktsiyani qo'llab-quvvatlash orqali Rett sindromi alomatlarini davolash uchun insulin o'xshash o'sish omilining 1 aminoterminal tripeptidining yangi sintetik analogi bo'lgan DAYBUE ni taklif etadi. Shuningdek, u Reyt sindromi va Lewy tana demensiyasi psixoziga olib keladigan Alzheimer kasalligi psixozini davolash uchun 2-bosqichli klinik sinovlarda bo'lgan remlifanserin; katta depressiya buzilishini davolash uchun 2-bosqichli klinik sinovlarda bo'lgan ACP-211; essensial tremor davolash uchun I bosqichli klinik sinovlarda bo'lgan ACP-711; va tardiv diskineziya hamda Huntington kasalligini davolash uchun GPR88 agonisti bo'lib, I bosqichli sinovlarda bo'lgan ACP-271 ni ishlab chiqmoqda. Muxarrir, shuningdek, Rett sindromi va mo'rt X sindromini davolash uchun 1-bosqichli klinik sinovlarda bo'lgan cGP analogi bo'lgan ACP-2591; va SYNGAP1 sindromini davolash bo'yicha kashfiyot dasturida bo'lgan STOKE Antisense Oligonucleotide dasturini ishlab chiqmoqda. U Rett sindromi va boshqa ko'rsatmalar uchun trofinetid bo'yicha Neuren Pharmaceuticals Limited bilan litsenziya shartnomasiga; va Markaziy Nerv tizimining og'ir va kam uchraydigan genetik neyrodegenerativ kasalliklarini potentsial davolash uchun yangi RNK asosidagi dorilarni kashf qilish, ishlab chiqish va tijoratlashtirish uchun Stoke Therapeutics, Inc. bilan litsenziya va hamkorlik shartnomasiga ega. Kompaniya avval Receptor Technologies, Inc. nomi bilan tanilgan va 1997 yilda ACADIA Pharmaceuticals Inc. nomini o'zgartirgan. ACADIA Pharmaceuticals Inc. 1993 yilda tashkil etilgan va San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Elizabeth H. Z. Thompson Ph.D. | Executive VP and Head of Research & Development |
| Mr. Albert S. Kildani | Senior Vice President of Investor Relations & Corporate Communications |
| Mr. James K. Kihara | Senior Vice President of Finance |
| Mr. Mark C. Schneyer | Executive VP & CFO |
| Mr. Scott Cenci | Senior VP, Chief Information & Data Officer |
| Mr. Thomas Andrew Garner | Executive VP & Chief Commercial Officer |
| Ms. Allyson McMillan-Youngblood | Senior Vice President of Rare Disease Franchise |
| Ms. Catherine E. Owen Adams | CEO & Director |
| Ms. Jennifer J. Rhodes J.D. | Executive VP, Chief Legal Officer & Secretary |
| Ms. Konstantina Katcheves | Senior VP, Chief Business & Strategy Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | acad-20260331.htm |
| 2026-05-06 | 8-K | acad-20260506.htm |
| 2026-05-01 | 8-K | acad-20260427.htm |
| 2026-04-24 | DEF 14A | acad-20260423.htm |
| 2026-04-24 | ARS | acad_2025_annual_report.pdf |
| 2026-03-05 | 8-K | acad-20260303.htm |
| 2026-02-26 | 10-K | acad-20251231.htm |
| 2026-02-25 | 8-K | acad-20260225.htm |
| 2026-01-13 | 8-K | acad-20260113.htm |
| 2025-11-06 | 10-Q | acad-20250930.htm |